Genetically engineered biological therapy of severe bronchial asthma with benralizumab

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Genetically engineered biological therapy (GEBT) of bronchial asthma (BA) is a modern method of treating severe forms of the disease that are uncontrolled by traditional pharmacotherapeutic approaches. Currently, six monoclonal antibody drugs for the treatment of severe bronchial asthma (anti-IgE – omalizumab), interleukin (IL)-5 antagonists (anti-IL-5 – mepolizumab, reslizumab) and its receptor (anti-IL-5Rα – benralizumab), as well as antibodies that selectively bind to the IL-4 and IL-13 receptor (anti-IL-4/13Rα - dupilumab) and tezepelumab, promoting the inhibition of thymic stromal lymphopoietin (TSLP) are registered in Russia.

A special group consists of patients with the eosinophilic phenotype of BA, characterized by a severe uncontrolled course and resistance to standard treatment regimens in accordance with the basic step therapy of the disease.

The article presents a clinical case of the effectiveness of GEBT using benralizumab as an example in a patient with severe uncontrolled bronchial asthma (eosinophilic phenotype).

Full Text

Restricted Access

About the authors

Elena Yu. Trushina

Penza Institute for Advanced Medical Training – Branch Campus of the Russian Medical Academy of Continuous Professional Education; Tambov State University named after G.R. Derzhavin

Author for correspondence.
Email: trushina.lena@mail.ru
ORCID iD: 0000-0001-5673-9195
SPIN-code: 2164-6580

Cand. Sci. (Med.), Associate Professor, Department of Pulmonology and Phthisiology, Associate Professor, Department of Hospital Therapy with a Course in Psychiatry, Institute of Medicine and Health Protection

Russian Federation, Penza; Tambov

Elena M. Kostina

Penza Institute for Advanced Medical Training – Branch Campus of the Russian Medical Academy of Continuous Professional Education

Email: trushina.lena@mail.ru
ORCID iD: 0000-0003-1797-8040
Russian Federation, Penza

Valery A. Tipikin

Penza Institute for Advanced Medical Training – Branch Campus of the Russian Medical Academy of Continuous Professional Education

Email: trushina.lena@mail.ru
ORCID iD: 0009-0000-0990-4661
Russian Federation, Penza

Ilya I. Illarionov

Penza Institute for Advanced Medical Training – Branch Campus of the Russian Medical Academy of Continuous Professional Education

Email: trushina.lena@mail.ru
ORCID iD: 0009-0008-0725-3242
Russian Federation, Penza

Ekaterina A. Orlova

Penza Institute for Advanced Medical Training – Branch Campus of the Russian Medical Academy of Continuous Professional Education

Email: trushina.lena@mail.ru
Russian Federation, Penza

Alina A. Turovskaya

Penza Institute for Advanced Medical Training – Branch Campus of the Russian Medical Academy of Continuous Professional Education

Email: trushina.lena@mail.ru
ORCID iD: 0000-0002-5138-808X
Russian Federation, Penza

References

  1. Global Initiative for Asthma. Difficult-to-treat and severe asthma in adolescent and adult patients: diagnosis and management. 2024 URL: https://ginasthma.org/wp-content/uploads/2024/11/GINA-Severe-Asthma-Guide-2024-WEB-WMS.pdf
  2. Клинические рекомендации. Бронхиальная астма. 2024. [Clinical guidelines. Bronchial asthma. 2024. (In Russ.)]. URL: https://cr.minzdrav.gov.ru/view-cr/359_3 (дата обращения / date of access: 20.03.2025).
  3. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2023. URL: https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-Full-Report-2023-WMS.pdf
  4. Holguin F., Cardet J.C., Chung K.F. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55,1900588. https://dx.doi.org/10.1183/13993003.00588-2019
  5. Huang K., Yang T., Xu J., et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. Lancet 2019;394:407–418. https://dx.doi.org/10.1016/s0140-6736(19)31147-x
  6. Княжеская Н.П., Анаев Э.Х., Камелева А.А. и др. Таргетная терапия бронхиальной астмы. Бенрализумаб: в фокусе внимания пациенты, принимающие системные глюкокортикостероиды. Медицинский совет. 2020;17:9–16. [Knyazheskaya N.P., Anaev E.Kh., Kameleva A.A. et al. Targeted therapy in bronchial asthma. Benralizumab: focus on patients using systemic glucocorticosteroids. Meditsinskiy sovet=Medical Council. 2020;(17):9–16. (In Russ.)]. https://doi.org/10.21518/2079-701X-2020-17-9-16
  7. Bourdin А., Brusselle G., Couillard S., et al. Phenotyping of severe asthma in the era of broad-acting anti-asthma biologics. J Allergy Clin Immunol Pract. 2024;12:809–823. https://dx.doi.org/10.1016/j.jaip.2024.01.023
  8. Chung K.F., Adcock I.M. Precision medicine for the discovery of treatable mechanisms in severe asthma. Allergy. 2019;74:1649–1659. https://dx.doi.org/10.1111/all.13771
  9. Pavlidis S., Takahashi K., Ng Kee Kwong F., et al. T2-high in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin. Eur Respir J. 2019;53:1800938. https://dx.doi.org/10.1183/13993003.00938-2018
  10. Agache I., Beltran J., Akdis C., et al. Efficacy and safety of treatment with biologicals(benralizumab, dupilumab, mepolizumab, omalizumab andreslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on theuse of biologicals in severe asthma. Allergy. 2020;75:1023–1042. https://dx.doi.org/10.1111/all.14221
  11. Ненашева Н.М., Курбачева О.М., Авдеев С.Н. и др. Практические рекомендации по выбору иммунобиологического препарата для лечения тяжелой бронхиальной астмы Т2-эндотипа. Пульмонология. 2020;30(2):227–244. [Nenasheva N.M., Kurbacheva O.M., Avdeev S.N., et al. Practical recommendations for choosing an immunobiological preparation for the treatment of severe bronchial asthma of T2-endotype. Russian Pulmonology. 2020;30(2):227?244. (In Russ.)]. https://dx.doi.org/10.18093/0869-0189-2020-30-2-227-244
  12. Edris A., De Feyter S., Maes T., et al. Monoclonal antibodies in type 2 asthma: a systematic review and network metaanalysis. Respir. Res. 2019;20(1):179. https://dx.doi.org/10.1186/s12931-019-1138-3
  13. Государственный реестр лекарственных средств. ЛП-000082. Ксолар (омализумаб). URL: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=d09dce42-ed01-4ff7-9c75-37757e0ff595
  14. Государственный реестр лекарственных средств. ЛП-004265. Синкейро (реслизумаб). [State Register of Medicines. LP-004265. Sinqueiro (reslizumab). (In Russ.)]. URL: https://grls.minzdrav.gov.ru/GRLS.aspx?isfs=0®type=1%2c6&pageSize=10&order=Registered&orderType=desc&pageNum=1&MnnR=реслизумаб&token=c25e49f9-7c5d-46c6-9d9b-4133c36b37db
  15. Государственный реестр лекарственных средств. ЛП-004794. Нукала (меполизумаб). [State Register of Medicines. LP-004794. Nucala (mepolizumab). (In Russ.)]. URL: https://grls.minzdrav.gov.ru/GRLS.aspx?isfs=0®type=1%2c6&pageSize=10&order=Registered&orderType=desc&pageNum=1&MnnR=меполизумаб&token=05e6b37f-7459-48b0-a331-0b3046264eee
  16. Государственный реестр лекарственных средств. ЛП-005492. Фазенра (бенрализумаб). [State Register of Medicines. LP-005492. Fasenra (benralizumab). (In Russ.)]. URL: https://grls.minzdrav.gov.ru/GRLS.aspx?isfs=0®type=1%2c6&pageSize=10&order=Registered&orderType=desc&pageNum=1&MnnR=бенрализумаб&token=d61cfb09-8d15-4959-835c-ddf3dcc34fcf
  17. Государственный реестр лекарственных средств. ЛП-005440. Дупиксент (дупилумаб). [State Register of Medicines. LP-005440. Dupixent (dupilumab). URL: https://grls.minzdrav.gov.ru/GRLS.aspx?isfs=0®type=1%2c6&pageSize=10&order=Registered&orderType=desc&pageNum=1&MnnR=дупилумаб&token=b77c8e34-d0ca-48d8-b997-bab7b4d38315
  18. Государственный реестр лекарственных средств. ЛП-005440. Тезспире (тезепелумаб). [State Register of Medicines. LP-005440. Tesspire (tezepelumab). (In Russ.)]. URL: https://grls.minzdrav.gov.ru/GRLS.aspx?isfs=0®type=1%2c6&pageSize=10&order=Registered&orderType=desc&pageNum=1&MnnR=тезепелумаб&token=ae5db859-7e6a-468a-891f-b1164c70aa61
  19. Agache I., Beltran J., Akdis C., et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy. 2020;75:1023–1042. https://dx.doi.org/10.1111/all.14221
  20. Малявин А.Г., Козулина И.Е., Шарапова Ю.А. Пять молекул для таргетной биологической терапии тяжелой бронхиальной астмы: реалии и перспективы. Терапия. 2020;5:195–205. [Malyavin A.G., Kozulina I.E., Sharapova Yu.A. Five molecules for targeted biological therapy of severe bronchial asthma: realities and perspectives. Therapy. 2020;5:195–205. (In Russ.)]. https://dx.doi.org/10.18565/therapy.2020.5.195–205
  21. Menzies-Gow A., Wechsler M.E., Brightling C.E. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21:268. https://dx.doi.org/10.1186/s12931-020-01505-x
  22. Передельская М.Ю., Ненашева Н.М. Перспективы в лечении тяжелой бронхиальной астмы – обзор новой молекулы тезепелумаб. Практическая аллергология. 2023;2:56–61. [Peredelskaya M.Yu., Nenasheva N.M. Perspectives in the treatment of severe bronchial asthma - review of the new tezepelumab molecule. Practical Allergology. 2023;2:56–61(In Russ.)]. https://dx.doi.org/10.46393/27129667_2023_2_56
  23. Lambrecht B.N., Hammad H. The immunology of asthma. Nat Immunol. 2015;16(1):45–56. https://dx.doi.org/10.1038/ni.3049
  24. Титова О.Н., Кузубова Н.А., Склярова Д.Б., и др. Эффективность бенрализумаба при лечении эозинофильного фенотипа тяжелой бронхиальной астмы в условиях реальной клинической практики. Пульмонология. 2021;31(5):628–634. [Titova O.N., Kuzubova N.A., Sklyarova D.B., et al. The effectiveness of benralizumab in the treatment of the eosinophilic phenotype of severe asthma in real clinical practice. Pul’monologiya. 2021;31(5):628–634. (In Russ.)]. https://dx.doi.org/10.18093/0869-0189-2021-31-5-628-634

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Figure. Clinical and inflammatory phenotypes of asthma. Adapted from [7]

Download (582KB)
Indexing metadata

Copyright (c) 2025 Bionika Media